Notably, leptin or adiponectin therapy alone cannot fully reverse lipodystrophy-associated metabolic abnormalities (6, 51), which might translate into a limited impact on cardiovascular phenotypes. This evidence concerns the gene ADIPOQ and lipodystrophy.